Look closer, and they’re quite different purchases. Alpha is a dual-technology system from FormaTK Systems, supplied in the UK by us. Hair removal is handled by the XLP Diode Laser, an 808 nm Extended Long Pulse system with two applicators: the 1.2 cm² ALD (Advanced Laser Diode) and the 4.5 cm² LLD (Large Laser Diode). Both run five treatment modes, including PowerMotion for high-fluence single-pass delivery, FineMotion for the fine, miniaturised hairs that remain later in a course, and SafeTone for melanin-rich skin. The same workstation carries a 3D IPL system, which extends the platform into selected pigmentation, vascular concerns, acne and skin rejuvenation, with more than 20 clinical applications across the complete system.

For a clinic owner, that changes the question from “which diode has the better specification?” to something more practical: what work will this machine actually do once it’s taking up space in a treatment room? It’s the main issue if you’re weighing up professional laser hair removal devices for a clinic that does more than hair removal.

Why Soprano Became the Default Name

Soprano earned its position. Alma built the range around SHR, in-motion delivery and strong contact cooling, then developed it through several generations, and in SHR In-Motion mode the practitioner repeatedly moves the applicator across the area, building heat gradually while contact cooling manages skin temperature. That counted commercially too, since comfort became something clinics could actively promote instead of just manage.

The current Soprano Titanium Special Edition combines 755 nm, 810 nm and 1064 nm wavelengths in a single simultaneous emission. ICE Plus provides continuous contact cooling, while the 4 cm² Trio MAX applicator is designed for larger treatment areas. Add years of brand recognition, and this isn’t an attempt to prove the familiar machine is obsolete.

The question is what Alpha does differently, and which Soprano you’re actually comparing it against.

Which Soprano Are You Actually Comparing Against?

“Soprano” is a family, not a single machine, and the differences between generations are big enough to change the comparison.

The original Soprano ICE is now well over a decade old. It delivers its three wavelengths through three separate applicators, one each for 755 nm, 810 nm and 1064 nm, each with a 1 cm² spot size, so the practitioner selects an applicator to suit the patient rather than treating with all three at once. Plenty of UK clinics still run one every day.

The Soprano ICE Platinum changed that by combining all three wavelengths in a single 2 cm² Trio applicator, firing them simultaneously. The Soprano Titanium kept the same triple-wavelength approach and roughly doubled the applicator again to 4 cm². Throughout this article, Soprano means the current Soprano Titanium, because that is the machine Alma sells today and the one a new purchase competes with.

The older models come into it if your clinic already owns one. Against an installed ICE or ICE Platinum, Alpha isn’t a sideways move between similar diodes: the 4.5 cm² applicator is a different working speed to a 1 cm² or 2 cm² handpiece, PowerMotion replaces applicator-swapping with continuous in-motion delivery, and the 3D IPL side adds a treatment menu no Soprano offers at any tier.

Alpha vs Soprano at a Glance

Technology and Wavelengths

Soprano has the more varied laser architecture. The Titanium platform combines 755 nm, 810 nm and 1064 nm wavelengths simultaneously. Alma positions the 755 nm component towards shallower targets and finer hair. It positions 810 nm as the central diode wavelength and 1064 nm as the deeper-penetrating component with lower melanin absorption.

For a clinic buying just for hair removal, that wavelength range is a strong part of Soprano’s case. However, the machine adjusts the wavelength distribution according to the Fitzpatrick skin type entered by the operator. For example, all three wavelengths are always fired, and the output is spread across the selected energy; a total output of 15 J may be 5 J of 755 nm, 5 J of 1064 nm and 5 J of 810 nm or other combinations depending on skin type. This may help explain reports of miniaturised hair during Soprano treatment courses, as potentially certain depths may not be getting a full therapeutic dose.

Alpha sticks with 808 nm and changes what the diode does with it. XLP stands for Extended Long Pulse. The pulse is shaped to diffuse heat evenly along the follicle so the bulge, matrix and dermal papilla reach the destruction threshold, which FormaTK puts at roughly 70°C held for 1 ms at the papilla, while Golden Touch Adaptive Cooling protects the epidermis. Alpha then offers five treatment modes around that 808 nm platform.

Single Mode delivers the selected energy in one pulse, for lighter skin with higher tolerance. PowerMotion delivers high-fluence pulses in one continuous pass. Fast Mode is a low-energy in-motion option, up to 10 J/cm² at up to 10 Hz, for cumulative heating, where that suits the patient, similar to the low-fluence in-motion approach used by Soprano. FineMotion builds heat around more superficial follicles, including miniaturised and vellus hairs. SafeTone heats gradually to protect the epidermis on melanin-rich skin and the darkest skin tones.

Soprano puts more wavelengths into its hair removal applicator but uses lower energies. Alpha uses one, gives the practitioner more ways to deliver it, then adds a separate IPL system on the same workstation.

Treatment Speed and Coverage

Soprano Titanium Special Edition has a 4 cm² Trio MAX applicator, with Alma publishing an improvement of up to 20% in treatment speed under specified conditions compared with its earlier configuration.

Alpha’s larger LLD applicator is 4.5 cm², and PowerMotion covers each area in one pass rather than several. FormaTK quotes up to three times faster treatments, and around five times faster than a traditional stamping technique over the same area. Those are manufacturer figures against manufacturer-chosen baselines.

Those figures can’t be used to determine a direct winner because manufacturers use different benchmarks and there is no controlled Alpha-versus-Soprano speed trial. If throughput matters, demo both machines and time the treatments that dominate your diary. Full legs and backs will tell you more than unrelated brochure percentages.

Skin Type Range

Soprano Titanium includes 1064 nm, which has lower epidermal melanin absorption than shorter hair removal wavelengths and is particularly relevant when treating darker skin. Alma positions the system for Fitzpatrick I to VI.

Alpha is also designed for Fitzpatrick I to VI and approaches darker skin from three directions rather than through a wavelength. SafeTone is a dedicated mode that heats the follicle gradually to protect the epidermis on melanin-rich skin and the darkest skin tones. Golden Touch Adaptive Cooling adjusts contact temperature during the treatment. And the Milo Melanin Meter measures melanin at each treatment spot to guide parameter selection, complementing rather than replacing a Fitzpatrick assessment. That helps where several practitioners share the same machine, and where a patient’s tone varies across treatment areas.

Our guide to device and wavelength selection for Fitzpatrick IV to VI explains why wavelength is only part of the decision. Cooling, pulse characteristics, fluence, patient selection and practitioner judgement matter too.

For clinics treating a large proportion of Fitzpatrick IV to VI patients, Soprano’s 1064 nm component deserves serious weight. Alpha’s case rests on SafeTone, adaptive cooling, objective melanin readings for each treatment area and the AlphaLine data across Fitzpatrick I to VI.

Comfort and Patient Experience

Soprano made comfort part of its identity early on. SHR builds heat progressively. The practitioner keeps the applicator moving over the area for repeated passes at lower fluence, and ICE Plus cools the skin while the temperature climbs. Patient comfort has also been a significant part of Soprano’s commercial appeal.

The cost of that approach is the passes themselves. Heat has to accumulate over several sweeps before the follicle reaches coagulation, so the result depends on the practitioner covering the area evenly for long enough, and a patch that gets fewer passes gets less energy. It also means more pulses per treatment. In FormaTK’s own comparison of delivery methods, low-fluence in-motion treatment needs multiple pulses to reach coagulation and consumes more pulses per session, which the manufacturer links to shorter applicator life.

PowerMotion takes the opposite route. FormaTK describes it as the first high-fluence in-motion technique. Each pulse carries enough energy to coagulate the follicle while the applicator continues moving, allowing the area to be covered in one pass rather than building heat over several. Alpha also keeps the low-fluence Fast Mode for patients who better tolerate the gradual heating, so the choice is made per patient rather than fixed by the machine.

On comfort itself, we wouldn’t claim one is inherently more comfortable. There isn’t a head-to-head study, and patient experience changes with hair density, area, parameters, skin type and operator technique. Alpha’s answer is Golden Touch Adaptive Cooling: a sapphire contact tip that draws heat from the skin, 18-karat gold plating inside the applicator that carries it away through the handpiece, and an algorithm that adjusts cooling through the treatment to balance comfort against efficacy. This is better judged during a live demo.

Fine and Miniaturised Hair

Every hair removal course ends up dealing with fine, miniaturised hair. Terminal hairs respond first; what remains by session five or six is thinner and paler, with less pigment available to absorb the energy, which means less heat reaches the follicle. The AlphaLine data quantifies it: by session five, around 80.5% of remaining hairs were classified as fine, and by session six, approximately 94.76%.

Low-fluence multi-pass delivery is at its weakest here. FormaTK’s published comparison lists higher vellus regrowth as a trade-off of the low-fluence in-motion approach, the reasoning being that a fine hair needs each pulse to count rather than relying on heat accumulating over repeated sweeps.

Alma’s answer to finer hair is a wavelength, with the 755 nm component of the Titanium positioned towards shallower targets. Alpha’s answer is a mode built for it. FineMotion is a controlled multi-pulse technique that builds heat at superficial follicle level, developed from the AlphaLine findings specifically for fine, miniaturised and vellus hair.

Neither approach has been tested against the other later in a course. What a clinic can check at a demo is whether the machine has a protocol for session six, not just session one.

Evidence

Soprano’s SHR technique has been studied in peer-reviewed trials since 2009, and its triple-wavelength systems have a growing body of published clinical data.

Alpha’s evidence is newer, but the AlphaLine France Project is notable for its scale. The observational project reports on 45,467 patients, approximately 200,000 sessions, and 338 clinics over around four years. Patients across Fitzpatrick I to VI are represented, and zero serious adverse events were reported within the dataset.

It also tracked how remaining hair changed as courses progressed. The fine-hair figures in the previous section come from that tracking, and FineMotion was developed in response to them.

AlphaLine isn’t a head-to-head Alpha-versus-Soprano trial and shouldn’t be presented as proof of superiority. Its value is that it reflects routine use across hundreds of working clinics.

Treatment Range

This is the point where the two systems stop being close substitutes. Soprano Titanium is built around hair removal. Alpha’s diode is only half of the platform. The 3D IPL side offers five applicators across two spot sizes: three 2 cm² 3D IPL S applicators at 430, 530 and 590 nm, and two 5 cm² 3D IPL L applicators at 530 and 650 nm. Wavelength is set by the applicator, while energy, pulse duration and contact cooling temperature can each be controlled independently. Those three controls are what the “3D” refers to. Tip cooling can be set to 5, 10 or 15°C, or switched off.

FormaTK’s argument is that overcooling constricts vessels in vascular work and drops the core temperature of pigment in pigmentation work, both of which force higher fluences, so being able to dial cooling back lets the end point be reached at lower energy. In practice, that covers selected pigmentation, vascular concerns, acne and post-acne erythema, and the Tight & Bright skin rejuvenation treatment.

For a dedicated hair removal clinic, that extra capability may add little. For a mixed aesthetics clinic, a single device that can perform both hair removal and IPL work may earn its treatment-room footprint more quickly.

We have also reviewed early evidence involving Alpha Pro 3D IPL for rosacea and facial telangiectasia. The case series is small and shouldn’t carry the same evidential weight as AlphaLine, but it demonstrates the additional work the IPL side is intended to cover.

Furthermore, Alpha’s S530 applicator runs the Tight & Bright treatment, where a second pass in Triple mode releases nine 5 ms pulses per second (three sub-pulses per shot at 3 Hz). This builds heat in the dermis to stimulate collagen while treating red and brown pigmentation, so the treatment addresses tone and texture in one session, similar to Sciton’s BBL.

Running Costs

Machine price alone doesn’t tell you enough. Compare the complete configuration, warranty, service cover, applicator replacement costs, consumables, training and what happens if the device is unavailable for a few days.

Then compare what each device lets one treatment room sell. A clinic running Soprano Titanium has a hair removal room. A clinic running Alpha has a room that covers the same hair removal diary and can also book pigmentation, vascular and skin rejuvenation work through the 3D IPL side. Getting that second treatment menu alongside a Soprano means a second device: a second purchase, a second service contract, a second training pathway and, in many clinics, a second room.

If you already own a capable IPL system, or your diary is full of hair removal, Alpha’s second platform may add little and Soprano’s dedicated architecture is the cleaner buy. The dual-platform argument is strongest for a mixed clinic that currently refers IPL work elsewhere or is considering two separate purchases to build out its treatment menu. For that clinic, the question isn’t which machine costs less. It’s which machine leaves less of the diary empty.

Training, Service and UK Support

A working laser needs more than good specifications. Someone needs to train practitioners, answer clinical queries, and deal with technical issues.

Alma has an established support structure for Soprano systems purchased through authorised providers, alongside treatment protocols and recommended settings.

Alpha is supplied in the UK by us, with device training plus ongoing clinical and technical support.

Ask who delivers training, whether additional staff can be trained later, what service cover includes and who the clinic calls when a problem appears halfway through a booked day. That’s when support stops being a line on a quote.

Which One Fits Your Clinic?

If hair removal is the centre of your business, Soprano Titanium makes a strong case. Its triple-wavelength architecture, established brand and longer clinical literature all count in its favour, especially if you have little need for IPL.

For a mixed aesthetics clinic, Alpha becomes more interesting. Hair removal sits alongside pigmentation, vascular and skin rejuvenation treatments, giving the same device more ways to earn its space.

Clinics treating a large proportion of Fitzpatrick IV to VI patients should examine the darker-skin protocols closely. Soprano’s 1064 nm component is significant, while Alpha combines SafeTone, adaptive cooling and Milo melanin readings for each treatment area, backed by AlphaLine data across Fitzpatrick I to VI.

Milo may also be useful where several practitioners share the same machine. Soprano supports consistency through established protocols and recommended settings, while Alpha adds a skin measurement that can inform parameter selection.

If you’re upgrading from an older Soprano ICE or ICE Platinum, the calculation is different again. You’re not comparing like-for-like machines. Applicator size, delivery method and treatment range all change, while Alpha’s 3D IPL platform adds treatments that aren’t available on Soprano. The range section above covers what that difference looks like in practice.

If price is driving the decision, look beyond the purchase figure. Run the numbers against realistic utilisation, service costs, treatment mix and the support attached to the device.

Frequently Asked Questions

What is the difference between the Alpha laser and Soprano?

Soprano Titanium Special Edition is a dedicated laser hair removal platform combining 755 nm, 810 nm and 1064 nm wavelengths simultaneously, delivered with SHR in-motion passes that build heat gradually at low fluences. Alpha uses an 808 nm XLP diode laser with five treatment modes, including high-fluence single-pass PowerMotion, FineMotion for fine hair and SafeTone for darker skin, and pairs it with 3D IPL. The main differences are the wavelength setup, how heat is delivered and the treatment range.

Can the Alpha laser treat darker skin types?

Alpha is designed for use across Fitzpatrick I to VI. It combines 808 nm diode energy with contact cooling, skin-specific protocols and Milo melanin guidance. Patient assessment and correct protocol selection remain essential.

What evidence supports the Alpha laser system?

The AlphaLine France Project reports on 45,467 patients, approximately 200,000 sessions and 338 clinics over around four years. The dataset includes Fitzpatrick I to VI and reports zero serious adverse events.

Is the Alpha laser a good upgrade from a Soprano ICE?

The original Soprano ICE uses separate single-wavelength applicators with a 1 cm² spot size, so moving to Alpha’s 4.5 cm² applicator with in-motion delivery is a significant change in working speed, and the 3D IPL side adds treatments the ICE can’t offer. If you own the newer ICE Platinum, the gap is smaller, but the IPL capability still applies. The comparison is against what your clinic owns now, which is worth raising at a demo.

What does the Alpha laser cost?

Pricing depends on the configuration, applicators and commercial package selected. We offer current pricing on enquiry.

What support does AMP provide with the Alpha laser?

We provide training with the Alpha system plus ongoing clinical and technical support, including help with treatment protocols and practitioner questions.

Does the Alpha laser need multiple passes like SHR?

No. In PowerMotion mode, each high-fluence pulse is designed to coagulate the follicle, so the applicator covers each area in one continuous pass. A low-fluence Fast Mode is available if gradual heating is preferred for a particular patient.

See the Alpha Laser Running

A specification sheet can tell you the wavelengths and spot sizes. It can’t tell you whether your practitioners like the handpiece, how quickly they can work through a full-leg treatment or whether the extra IPL capability will actually earn money in your clinic.

If you’re considering Alpha as a Soprano laser alternative, view the full Alpha Laser System page or contact us to arrange a demonstration.

Soprano, Soprano Titanium, SHR, In-Motion and ICE Plus are trademarks or registered trademarks of Alma. Alma is not affiliated with AMP or the Alpha Laser System. Comparative statements in this article are based on publicly available manufacturer information current at the time of writing. Alpha and associated technology names are products or technologies of FormaTK Systems.

The post Alpha Laser vs Soprano: How Do the Diode Lasers Compare? appeared first on Aesthetic Medical Partnership.

In regenerative medicine, experience matters. When a practitioner has spent more than two decades working across trauma, orthopaedics, aesthetics and regenerative medicine – while also training healthcare professionals internationally – their choice of technology carries weight.

That is why the experience of Claudia McGloin RGN is particularly relevant for practitioners considering Platelet-Rich Plasma (PRP) and autologous regenerative treatments.

As Clinical Director of The Regenerative Expert Nurse Clinic in Sligo, Ireland, Claudia has built a reputation as one of the country’s leading authorities on PRP and regenerative medicine. With more than 28 years of nursing experience and over 16 years dedicated to regenerative and aesthetic medicine, she combines extensive clinical expertise with a strong commitment to education, research and patient safety.

Today, Cellenis® PRP and Cellenis® DermaFiller form an important part of her treatment offering. The decision to adopt the systems was not driven by marketing claims or headline platelet counts. It was driven by the science behind the technology and the consistency of the product being produced.

A Career Dedicated to Regenerative Medicine

Claudia’s career spans advanced trauma and orthopaedic nursing, aesthetics, women’s health, hair restoration, intimate wellness and regenerative medicine.

She serves on the Editorial Boards of both the Journal of Aesthetic Nursing and Aesthetic Medicine, regularly publishes peer-reviewed articles and presents internationally on regenerative medicine and PRP.

She is also a Key Opinion Leader and international trainer for Cellenis, helping healthcare professionals better understand evidence-based PRP applications across multiple indications.

Her clinic specialises in a broad range of regenerative and restorative treatments, including skin rejuvenation, hair restoration, orthopaedic applications, women’s health and menopause support, intimate wellness and advanced regenerative medicine. This breadth of experience allows her to see first-hand how regenerative medicine can be applied across a wide range of patient needs.

Across all of these indications, one principle remains constant: the quality of the PRP matters.

“I’ve spent years educating practitioners on PRP variability and why not all systems produce the same product. The details matter.” – Claudia McGloin

Why Cellenis® Caught Her Attention

Having worked with multiple PRP systems throughout her career, Claudia was particularly interested in the scientific principles behind Cellenis.

Rather than focusing solely on platelet concentration, she looked at the wider factors that influence PRP quality and clinical outcomes. This included platelet preservation, the effectiveness of the separation technology, anticoagulant formulation, product consistency and the ability to achieve reproducible results from treatment to treatment.

These factors all contribute to the quality of the final platelet-rich plasma preparation and can ultimately influence treatment outcomes.

In a field where results can vary significantly depending on the system being used, Claudia believes practitioners need confidence that they are delivering a consistent product every time.

“My expectation was simple: a system grounded in science that could support a more consistent and evidence-based approach to regenerative medicine.”

Supporting a Wide Range of Treatments

At The Regenerative Expert Nurse Clinic, regenerative medicine forms part of a wide range of treatment pathways. Cellenis PRP supports treatments including:

• Facial rejuvenation
• Hair restoration
• Orthopaedic applications
• Intimate wellness
• Menopause-related concerns

According to Claudia, one of the greatest strengths of the system is its versatility.

Rather than viewing PRP as a standalone procedure, she incorporates it into broader treatment plans designed to support tissue repair, restoration and regeneration.

“What Cellenis allows me to do is incorporate the patient’s own biological resources across a wide range of indications while maintaining the same regenerative philosophy throughout the clinic.”

Real Patient Feedback

One patient who had received PRP treatments for more than 14 years using several different PRP systems became one of Claudia’s first Cellenis patients.

The feedback was immediate. At follow-up, the patient reported brighter skin, improved texture and a reduction in the appearance of fine lines around the eyes. Most importantly, she felt the results exceeded those she had experienced with previous PRP systems.

For Claudia, this was particularly significant because the patient had extensive experience of PRP treatments and was uniquely positioned to compare outcomes.

“She told me that, in her opinion, the Cellenis treatment had given her the best result she had seen.”

The Growing Role of Cellenis® DermaFiller

Alongside PRP, Claudia has also seen strong patient interest in Cellenis DermaFiller.

Created from the patient’s own plasma, DermaFiller offers a regenerative option for patients seeking subtle volume restoration while also supporting tissue quality. For many patients, this biological approach is particularly appealing.

“I’ve worked with many PRP kits over the years, and nothing compares to Cellenis. The results I see with Cellenis PRP and DermaFiller are exceptional. My patients love that this is their own body’s filler, made from their own growth factors. They much prefer this to synthetic fillers.”

Patient Perspective

“PRP filler gave me back the structure and strength my skin had lost. It looks firmer, healthier and years younger without looking overdone.” – Margaret, 59

“I didn’t want to look like I’d had ‘work done’ – just fresher. PRP filler was perfect. My skin looks revived, plump and healthy. People say I look well, not different.” – Joanne, 61

Raising Standards Through Education

Beyond clinical outcomes, Claudia believes one of the biggest opportunities within regenerative medicine is education.

Patients are asking more informed questions and practitioners increasingly want to understand not just what a system does, but why it works. As regenerative medicine continues to develop, she believes greater understanding will help raise standards across the sector.

“I would encourage practitioners to look beyond the marketing and really understand how a system works. Ask questions, review the evidence, undertake training and understand why one system may differ from another.”

For practitioners considering PRP, her advice is straightforward: invest in education first, understand the science, focus on quality and never stop learning.

About Claudia McGloin RGN

Claudia McGloin is an internationally recognised Regenerative Medicine Expert, Orthopaedic Nurse Practitioner and one of Ireland’s leading authorities on Platelet-Rich Plasma therapy.

With more than 28 years of nursing experience and over 16 years specialising in regenerative medicine and aesthetics, she is an international speaker, educator, author and Key Opinion Leader for Cellenis.

She is Clinical Director of The Regenerative Expert Nurse Clinic in Sligo, Ireland, where she provides regenerative treatments across aesthetics, orthopaedics, hair restoration, intimate wellness and women’s health.

Why Aesthetic Medical Partnership?

We bring together evidence-based technologies and in-clinic support to help you build treatment protocols tailored for the modern aesthetic patient. By working with AMP, clinics gain not just a supplier, but a committed partner in long-term growth. Partner with us today to transform your practice and elevate your patient outcomes.

A Partnership Built on Shared Values

Claudia’s relationship with AMP UK extends beyond products. She describes the partnership as being built around a shared interest in education, patient safety and helping practitioners make informed decisions about regenerative treatments.

Rather than focusing solely on product supply, the relationship has centred on discussion, training, evidence and professional development.

“What appealed to me about AMP UK was that our conversations were never just about products. We talked about the science behind PRP, patient safety, education, standardisation and some of the challenges facing regenerative medicine as a speciality.”

She continues: “For me, the best partnerships are built on shared values.”

Martyn Roe, Director of AMP UK, added: “We are delighted to be working with Claudia. Few practitioners can match the breadth of her experience in regenerative medicine and PRP. Having lectured internationally and worked with a wide range of PRP systems over many years, her insights are grounded in extensive clinical experience rather than marketing claims.”

“That perspective makes her assessment of different technologies particularly valuable. Claudia understands the strengths and limitations of PRP systems because she has used them in practice, across a broad range of indications and patient groups. Her decision to incorporate Cellenis PRP into her clinic reflects many of the qualities that attracted us to the technology in the first place, including its ability to deliver highly concentrated platelets while minimising red blood cells and inflammatory aspects of white blood cells.”

“We are also excited to be developing an educational programme with Claudia in the coming months, providing practitioners with opportunities to learn from her extensive clinical knowledge and real-world experience of regenerative medicine. Watch this space.”

Looking Ahead

Claudia believes patient expectations are changing. Increasingly, patients are looking for treatments that work with their body’s own biology rather than simply masking signs of ageing.

As awareness of regenerative medicine continues to grow, she expects demand for evidence-based treatments such as PRP and biological fillers to increase. For clinics looking to embrace this shift, she believes systems that prioritise product quality, reproducibility and clinical confidence will play an increasingly important role.

“For me, Cellenis represents more than a PRP system. It reflects the direction regenerative medicine needs to take – with greater emphasis on quality, consistency, education and patient outcomes.”

Contact Us Today

Visit: www.amp-uk.co.uk

Call: 01727 482 432

Email: info@amp-uk.co.uk

WhatsApp: 07771 131 900

The post Why One of Ireland’s Leading Regenerative Medicine Experts Chooses Cellenis® appeared first on Aesthetic Medical Partnership.

Conducted across France in partnership with Keros Technology, the AlphaLine France Project is an ongoing, real-world observational study of the Alpha Laser System and its 808 nm XLP diode laser. Rather than a tightly controlled trial run in a single academic centre, it captures how the platform performs in routine commercial practice, the same conditions a UK clinic works in every day.

One of the Largest Real-World Evidence Bases in Laser Hair Removal

Most published evidence on laser hair removal comes from controlled research in hospitals, universities, or single private clinics. The largest peer-reviewed diode cohorts to date run to roughly 1,000 patients. The AlphaLine France Project documents 45,467 patients and around 200,000 treatment sessions across 338 working commercial clinics, treating ordinary consumer patients in routine practice.

What stands out is not only the volume, but the consistency. Across 338 independent clinics and roughly four years of continuous use, treatment parameters, workflows and biological outcomes proved reproducible to a degree that is unusual in real-world data of this size. For a clinic owner, that reproducibility is the point: it is evidence the platform delivers predictable results in the field, not just in ideal conditions.

The Biological Inflection Point: Why Sessions 4 to 6 Change Everything

The project’s defining finding is that hair removal is not a single, repeated event. It is a biological journey in which the follicle itself transforms.

Sequential analysis showed a clear transition between the fourth and sixth sessions. Residual follicles shift from coarse terminal hairs to fine, miniaturised structures:

• By Session 5, around 80.5% of remaining hairs were classified as fine
• By Session 6, that figure rose to approximately 94.76%

In other words, by the mid-point of a treatment course the target has fundamentally changed. Fine and miniaturised hair holds heat differently to coarse terminal hair, which is why a device that can adapt its delivery, rather than repeat a fixed setting, matters so much in the later stages of a course.

Tellingly, clinicians across the network independently lengthened their treatment intervals over a course, from around 9 weeks early on to roughly 14 weeks in later sessions. Hundreds of clinics converging on the same timing pattern, without being told to, is an independent real-world signature of exactly that follicular shift.

Fewer Sessions, Stronger Clinic Economics

When protocols adapt to the changing follicle, patients finish sooner. In the AlphaLine dataset, treatment courses were completed in approximately 6.68 sessions on average, against a commonly cited industry benchmark of 8 to 10.

That is roughly 25 to 33% fewer visits per patient, and it flows straight to the bottom line:

• Higher clinic throughput and better use of each treatment chair
• Shorter time to completion, which improves patient satisfaction and referrals
• Stronger per-course economics without cutting corners on results

For a clinic weighing up a diode laser purchase, this is the commercial case in one line: the same result in fewer appointments.

A Platform Built to Adapt

The Alpha Laser System is designed as an ecosystem rather than a single fixed protocol, because no one delivery method suits every patient, body area or stage of treatment. It combines:

• Five treatment modes, each matched to a specific follicular stage, skin type and anatomy: Single Mode and PowerMotion for early, coarse-hair phases; Fast Mode for fast, comfortable in-motion treatment; FineMotion for fine, superficial and miniaturised hair in the later stages; and SafeTone for safe, effective treatment on darker skin types
• XLP Golden Touch cooling, a sapphire and 18-karat gold-plated handpiece with an adaptive cooling algorithm that continuously balances patient comfort against clinical effect, protecting the epidermis across long sessions
• MILO objective melanin assessment, which uses diffuse reflectance spectroscopy to measure epidermal melanin and support individualised, safer parameter selection across diverse skin types
• 3D IPL technology integrated into the same platform

Notably, FineMotion was developed directly out of the AlphaLine findings, purpose-built for the fine-hair challenge the data revealed in the later stages of a course.

Safety and Durability at Commercial Scale

Evidence at this scale also speaks to safety and build quality, two things that matter enormously when a device is treating patients day in, day out:

• Zero serious adverse events were reported across approximately 200,000 sessions, spanning the full Fitzpatrick I-VI range and both genders
• 152 of the 338 clinics (around 45%) had been running the Alpha System for 18 or more months of continuous use at the time of analysis

In a category where capital equipment is often rotated out or shelved, nearly half the installed base staying in daily service for 18 months and beyond is a strong real-world signal of clinical confidence, workflow fit and engineering reliability.

A Broad, Real-World Patient Mix

The findings reflect a genuine cross-section of aesthetic practice rather than a narrow study cohort. Treatment spanned the full Fitzpatrick I-VI spectrum, with types V and VI making up around 9% of patients, treated successfully on the same platform with parameters guided by MILO melanin readings and SafeTone where appropriate. Around 65% of sessions fell in the core 20 to 40 age bracket, and treatment covered the full anatomical map: face, beard, neck, armpits, chest, back, abdomen, bikini, buttocks, hands and legs.

One figure worth flagging for UK clinics is the gender split: approximately 93% female to 7% male. Male laser hair removal is among the fastest-growing segments in aesthetics, and it is dominated by exactly the dense, coarse terminal hair the Alpha System’s modes are engineered to handle. For clinics, that 7% points less to a technology gap and more to an open commercial opportunity in marketing and positioning.

Support That Goes Beyond the Equipment

Aesthetic Medical Partnership is the UK distributor of the Alpha Laser System. As with every device in our range, our role does not end at supply. We work alongside clinics with training, marketing support and ongoing clinical guidance, so new treatments are introduced with confidence and start earning quickly.

Evidence like the AlphaLine France Project is a large part of why we partner with the platforms we do. It gives UK clinic owners something firmer than a specification sheet: proof, at real scale, that the technology performs, stays safe across skin types and keeps delivering over years of commercial use.

Why Aesthetic Medical Partnership?

We bring together evidence-based technologies and in-clinic support to help you build treatment protocols tailored for the modern aesthetic patient. By working with AMP, clinics gain not just a supplier, but a committed partner in long-term growth.

Join the movement.

Partner with us today to transform your practice and elevate your patient outcomes.

The post Case Study: Inside the AlphaLine France Project, the Real-World Evidence Behind the Alpha Laser System appeared first on Aesthetic Medical Partnership.

But the same device that performs predictably on lighter skin can behave very differently on Fitzpatrick IV to VI. Treating darker skin well is not about doing less; it is about doing it differently, with a clear understanding of the underlying physics and a disciplined, evidence-led approach.

This guide sets out the principles practitioners need to select devices and wavelengths confidently, and to raise the standard of care for every patient who walks through the door.

Why Darker Skin Needs a Different Approach

The defining feature of darker skin, clinically, is increased epidermal melanin, alongside more reactive melanocytes and fibroblasts. For energy-based devices, melanin is a competing chromophore: it absorbs light and laser energy that is intended for another target, such as the hair follicle, a vascular lesion or water in the dermis. When that absorbed energy is concentrated in the epidermis, it generates unwanted heat where you least want it.

The clinical consequences are well documented. Compared with lighter skin, darker skin carries a greater risk of dyspigmentation and scarring, and individuals with Fitzpatrick IV to VI are more prone to prolonged erythema, pigmentary change and scarring following treatment. Post-inflammatory hyperpigmentation (PIH) is the complication practitioners encounter most, and it can be slow to resolve and distressing for patients.

It is worth distinguishing epidermal PIH, which is more superficial and generally more responsive, from dermal pigment, which sits deeper and clears more slowly. This distinction should inform both the modality you choose and the timeline you discuss with the patient.

None of this contraindicates treatment. It simply means device selection, parameters and protocol all have to work harder to protect the epidermis.

Assessing the Patient: Fitzpatrick and Beyond

Patient selection is your first and most important safety control. The Fitzpatrick scale remains the standard starting point, but treat it as a starting point rather than a full picture. It relies partly on self-reported burning and tanning history; it can under-classify constitutive pigment in some patients, and a recent tan can shift facultative melanin well above someone’s baseline. Objective skin-typing tools, including melanin-reading diagnostics built into modern platforms, can support a more reliable assessment and remove some of the guesswork.

A thorough history matters as much as the type itself. Ask specifically about previous PIH or a tendency to mark after minor trauma, any history of keloid or hypertrophic scarring, recent or planned sun exposure, and photosensitising medication.

Establish what the patient has had done before and how their skin responded. Set expectations early: for darker skin, conservative, staged treatment is typically the safest route to a good result, and that conversation is easier before the first session than after a complication.

Principles of Wavelength and Device Selection

The governing principle is straightforward. Longer wavelengths penetrate more deeply and are less readily absorbed by epidermal melanin, so they tend to spare the epidermis. This is why the long-pulsed 1064nm Nd:YAG is widely regarded as the gold standard for laser hair removal in darker skin. At the other end of the scale, fully ablative resurfacing is generally avoided in darker skin because of the pigmentary risk, while non-ablative modalities are preferred for their faster recovery and lower adverse-event profile.

Non-ablative fractional resurfacing is one area where the evidence has matured considerably. The wavelengths used by MultiFrax (1550nm erbium glass and 1927nm thulium) are precisely those studied most in darker skin.

A 2026 review of the dual 1550nm/1927nm fractional system in skin of colour (Fitzpatrick III to VI) reported consistent improvement across studies, though PIH rates varied between them. The wider evidence base consistently links lower energy and density, fewer passes and integrated cooling to a reduced risk of PIH.

Separately, the 1550nm wavelength has shown safety and efficacy for acne scarring in types IV to VI, with the important caveat that self-limited PIH was more common at higher densities. Low-energy, low-density 1927nm has been used to improve existing PIH in darker skin.

The clinical message is consistent: the technology can serve darker skin well when it is used conservatively. For depth on how the two wavelengths work, see our existing MultiFrax wavelength article.

Intense pulsed light demands the most caution. Because IPL delivers a broad spectrum of light, including shorter wavelengths that melanin absorbs strongly, the competition between epidermal pigment and the intended target is at its greatest.

Robust contact cooling, appropriate cut-off filtering and careful parameter control all make a meaningful difference, and the Alpha diode laser and 3D IPL system is built around those controls exactly. Even so, they do not remove the need for rigorous patient selection. IPL should be approached conservatively in Fitzpatrick IV, with particular care as you move towards V and VI, and always guided by the device instructions for use.

Safer-Practice Settings and Protocols (Principles, Not Parameters)

Exact fluences, densities and pulse settings belong in the device IFU (Instructions for Use) and in hands-on training, and they vary by platform, indication and individual patient. What does generalise is the set of principles that reduce risk.

Published guidance for energy-based treatment in darker skin consistently points to longer wavelengths, the minimum effective fluence, lower density, fewer passes, appropriate cooling and longer intervals between sessions.

In practice, that means starting conservatively and building gradually rather than chasing a result in a single aggressive session. A test patch in a representative but discreet area is good practice in higher Fitzpatrick types. Reviewed after an appropriate interval before you commit to a full treatment, it helps you read how an individual’s skin responds.

Allow generous healing time between sessions, keep cooling consistent throughout treatment, and document settings and results so each session informs the next. Treat to a conservative clinical endpoint rather than the most visible immediate reaction, and stop sooner rather than later if the skin response exceeds what you expected. When the device IFU and your training conflict with what feels commercially tempting, follow the IFU.

Reducing the Risk of PIH Before and After Treatment

Much of the work that prevents PIH happens around the treatment rather than during it. Before treatment, strict photoprotection is non-negotiable: broad-spectrum, high-SPF sunscreen, ideally with iron oxides for additional visible-light protection. The patient should also avoid treatment if their skin has recently tanned, since prior sun exposure and epidermal disruption both worsen PIH risk.

Where clinically appropriate and under the relevant prescriber’s direction, priming the skin with topical agents such as retinoids or depigmenting preparations may help. This is a decision for the treating clinician within prescribing rules rather than a blanket recommendation.

Afterwards, gentle aftercare, continued cooling and disciplined sun avoidance support recovery and limit reactive pigmentation. Expectation-setting is part of risk management, too. Outcomes in darker skin are often achieved over a course of treatments rather than in one. Improvement is gradual, and conditions such as melasma are prone to recurrence and are typically managed alongside topical therapy. Framing the goal as a visible improvement, maintained over time, rather than a one-off “fix”, protects both the patient and the clinic.

When to Proceed With Caution or Refer

Some presentations call for a pause. A history of keloid or hypertrophic scarring, a recent tan, recent isotretinoin use, active or unstable inflammatory skin disease, photosensitising medication, or unrealistic expectations should all prompt a more cautious plan or a deferral.

Any pigmented lesion where the diagnosis is not clear belongs with a dermatologist before any energy is applied, not in a cosmetic treatment chair. The most experienced practitioners are comfortable saying “not today” or “not with this device”, and that conservative judgement is itself a marker of a high-standard clinic.

Building Confidence in Your Team

Safe, confident treatment of darker skin is a capability you build, not a setting you select. It comes from understanding the science, knowing your device’s IFU thoroughly, and having protocols and patient-selection guidance you can rely on. This is where the right supplier relationship earns its keep.

We support partner clinics with hands-on training, treatment protocols and patient-selection guidance, backed by a clinical and KOL (Key Opinion Leader) network. This is so your team can offer treatments across diverse skin types with genuine confidence rather than caution born of uncertainty. Investing in that knowledge is what turns a capable device into a reliably safe service.

Talk to AMP About Treating Diverse Skin Types

If you are selecting or expanding energy-based capability and want it to serve every patient safely, we can help you match the right device and training to your clinic. Explore the full medical aesthetic device range, or get in touch to discuss device selection and training for Fitzpatrick IV to VI.

FAQs

Is laser treatment safe for darker skin types?

Yes, when the device, wavelength, settings and protocol are chosen appropriately. Modern non-ablative and longer-wavelength technologies have a well-established safety record in Fitzpatrick IV to VI, but darker skin carries a higher risk of post-inflammatory hyperpigmentation, so conservative settings, careful patient selection and proper cooling are essential. Exact parameters should always follow the device instructions for use and accredited training.

Which wavelengths are safer for darker skin?

As a general principle, longer wavelengths are safer because they penetrate more deeply and are less absorbed by melanin in the epidermis. The 1064nm Nd:YAG is widely considered the gold standard for hair removal in darker skin, and non-ablative fractional wavelengths such as 1550nm and 1927nm have a strong evidence base for resurfacing and pigmentation when used at conservative energy and density.

How can clinics reduce the risk of PIH in darker skin?

Before treatment, use strict photoprotection and avoid treating recently tanned skin. During treatment, favour longer wavelengths, the minimum effective fluence, lower density, fewer passes and consistent cooling, with longer intervals between sessions. Afterwards, support recovery with gentle aftercare and sun avoidance. A test patch in higher Fitzpatrick types helps gauge individual response before a full treatment.

Can IPL be used on Fitzpatrick IV to VI?

IPL requires the most caution of any light-based modality in darker skin because its broad spectrum is strongly absorbed by epidermal melanin, raising the risk of burns and pigmentary change. It can have a role in carefully selected patients when delivered with appropriate filtering, robust cooling and conservative settings, with the greatest care as skin type increases towards VI. Rigorous patient selection and the device instructions for use should always guide the decision.

What should practitioners assess before treating darker skin?

Start with Fitzpatrick type, but go further: assess constitutive pigment objectively where possible, take a history of PIH and keloid or hypertrophic scarring, check for recent sun exposure or tanning, review photosensitising medication, and understand previous treatment responses. Set realistic expectations about staged treatment and recurrence, and refer any pigmented lesion of uncertain diagnosis for dermatological review before treatment.

The post Treating Darker Skin Safely: Device and Wavelength Selection for Fitzpatrick IV to VI appeared first on Aesthetic Medical Partnership.

His latest addition? The MultiFrax laser – a breakthrough portable device that, in his words, “delivers the power of much bigger systems in the palm of your hand.”

“The MultiFrax is a really unique piece of kit. It offers dual non-ablative fractional wavelengths – 1550 nm and 1927 nm – allowing us to treat both superficial pigmentation and deeper dermal concerns in a single session. That’s versatility I can use with almost any patient,” he explains.

Unlike traditional lasers that require a dedicated room and lengthy setup, the MultiFrax is handheld and battery-powered. “I’m blessed with a lot of lasers at PHI, but whenever I plan a treatment, it usually means moving rooms or rescheduling. With MultiFrax, I can demonstrate, patch-test, or even treat during any appointment—it’s transformative for workflow and patient experience,” he adds.

Dr Patel highlights the minimal downtime and comfort his patients appreciate: “Most sessions don’t require anaesthetic, and recovery is just two to five days—significantly less than fully ablative systems.. And would I recommend that others look at the MultiFrax for themselves and what it can bring to their practice? Absolutely!”

The MultiFrax Advantage

Bringing hospital-grade technology into a portable format, MultiFrax is the world’s first high-powered 1550 nm / 1927 nm handheld laser. Key features include:

• Dual Wavelengths in one pass
  Thanks to SimulScan technology, both 1550 nm and 1927 nm can be delivered
  simultaneously.
• Clinical Versatility
  Treat acne scars, wrinkles, pigmentation, actinic keratoses,
  sun damage, and texture concerns in one device.
• Smart Roller Tip
  Only activates on skin contact, delivering precise
  microbeams in rows for consistent coverage.
• Patient-Friendly
  Minimal downtime, little to no anaesthetic, and visible
  results that build patient loyalty.
• Economic Efficiency
  Up to 90% lower cost per use compared to competing
  technologies, with no costly consumables.
• Portability
  Untethered, compact, and designed for any clinic environment.

Why Aesthetic Medical Partnership?

We bring together evidence-based technologies and in-clinic support to help you build treatment protocols tailored for the modern aesthetic patient. By working with AMP, clinics gain not just a supplier, but a committed partner in long-term growth.

Join the Movement.

Partner with us today to transform your practice and elevate your patient outcomes.

The post A Portable Revolution in Skin Rejuvenation: Dr Tapan Patel on the MultiFrax Laser appeared first on Aesthetic Medical Partnership.

For a clinic weighing whether to adopt them, the marketing tends to skip the question that matters most: where the exosomes come from. Source is not a detail. It shapes the consistency you can expect from batch to batch, the safety profile you are accountable for, the regulatory position of the product and how you can compliantly use it in your treatment room.

It also narrows the decision more than most clinics realise. You will see three sources marketed (plant, animal and human), but only two of them are topical cosmetic options that UK clinics can lawfully choose between today.

This article sets out the practical differences so you can make an informed adoption decision, and explains why the real choice comes down to plant versus animal.

A Quick Explainer on Exosomes

Exosomes are nanoscale extracellular vesicles (microscopic packets that carry signals between cells). They act as carriers, transporting proteins, peptides, lipids and other signalling factors between cells and contributing to the body’s natural communication and repair processes.

In an aesthetic context, the interest lies in that signalling role and the potential to support skin during recovery from procedures that temporarily disrupt the barrier.

We have covered the underlying cell-signalling science in more depth in our piece on secretome signalling in skin, so this article focuses on the source decision rather than repeating the biology.

Why the Source Matters

Not all exosomes are the same, and treating them as a single category is the most common mistake we see. The biological origin of an exosome preparation determines four things a clinic genuinely cares about:

• How consistent the product is from one batch to the next.
• The safety and traceability of the raw material.
• The regulatory status of the finished product in the UK.
• The route by which it can be applied.

A product that performs well on one of these measures may fall short on another, so the source comparison is best made across all four at once rather than on headline efficacy alone.

Human and Stem-Cell-Derived Exosomes: The Hyped Option That Is Not on the Table

Human and stem-cell-derived exosomes are isolated from human biological material, such as mesenchymal stem cells or donor tissue. They attract much of the attention because human-derived exosomes feature prominently in the early research. Proponents also describe them as the gold standard for signalling payload.

For a UK clinic, though, they are not an option that can simply be added to the treatment menu. Because the starting material is biological and donor-dependent, batch-to-batch variability and traceability of the source are recognised issues, and standardisation across the sector is still developing.

The decisive factor is regulatory. Human-derived exosomes are not approved for cosmetic use, and the route by which they tend to be promoted internationally (injection) falls under medicines regulation in the UK. That places them outside what a clinic can compliantly offer today, which is why much of the exosome hype describes a product that is not actually available to you.

Animal-Derived Exosomes

Animal-derived exosomes are the other topical option a UK clinic will encounter, and they sit within the cosmetics framework in much the same way plant-derived products do. Sources vary widely, from bovine colostrum to fish and red deer material.

The main argument made for animal-derived material is biological proximity. Because it comes from animal cells, proponents argue it carries signalling factors more closely matched to human biology than a single plant source can offer, and therefore claim better compatibility with human skin.

That argument is worth taking seriously, but it comes with the trade-offs you would expect from animal-sourced biological material: questions around sourcing, traceability and batch-to-batch consistency, as well as some patients’ concerns about animal-derived ingredients. It’s also the specific claim that the plant-derived approach set out below is formulated to answer.

Plant-Derived Exosomes (PDENs)

Plant-derived exosomes, more precisely described as plant-derived extracellular nanoparticles (PDENs), are produced from plant stem cells rather than human or animal tissue. They function as biomimetic carriers, delivering factors that are compatible with the skin and intended to complement its own signalling environment.

The idea that plant compounds can act on human biology is nothing new. The caffeine in your morning coffee and the salicylic acid in your cleanser both come from plant chemistry, while many medicines also have plant-derived origins.

Plant-derived signalling factors are the same principle, one step on.

The case for plant-derived material rests first on the source. Cultivating from plant stem cells allows for a controlled, repeatable starting point, which supports greater consistency from batch to batch. It also removes both the donor-sourcing questions of human material and the animal-sourcing and traceability questions above.

The recognised limitation of plant material is the mirror image of the animal camp’s pitch. No single plant source carries the full range of human-compatible signalling factors. On its own, a single-source plant exosome has limited ability to move beyond the skin surface without an effective delivery system.

This is precisely the gap that formulation, rather than source alone, is designed to close, and it is where the specific product matters more than the broad category (see EXO|E below).

The clinical evidence base for PDENs is still emerging. Early casework has been reported in scar and post-procedure recovery contexts, so claims should be framed accordingly and expectations set realistically with patients.

What Else Is in the Bottle?

A lot of exosome products are formulated with other actives, most often added hyaluronic acid. That matters, because the point of an exosome product is signalling: prompting the skin’s own processes rather than topping it up with material from outside. EXO|E contains no added hyaluronic acid or other filler actives. What’s in the syringe is the plant stem cell secretory factors and the delivery system that carries them.

Practitioners using EXO|E report improvements in hydration and plumpness over the course of the protocol, which is what you’d expect from a product that supports the skin’s own hydration rather than supplying it.

How They Compare for a Clinic

The table below sets out the comparison across the factors that drive an adoption decision. It is a general guide, and individual products vary, so always assess the specific product and its documentation.

What This Means for Your Treatment Menu

For a UK clinic, the comparison narrows to a real, two-way decision. Human-derived material, whatever its research profile, is not a compliant topical option today. That leaves plant- and animal-derived products as the practical choices for a clinic that wants to introduce an exosome-based step. The deciding question becomes which source gives you consistency and a clean sourcing story without giving up biological compatibility.

This is where our flagship plant-derived range fits. EXO|E uses patented biomimetic PDENs technology and, rather than relying on a single botanical source, blends multiple plant stem cell extracts. This formulation is designed to address the compatibility limitation of single-source plant products while retaining the sourcing and traceability advantages of plant-derived material.

Our DE|RIVE range extends the same plant-derived approach. The goal is to give clinics a consistent, well-documented product with a clear sourcing story. Adoption is a measured addition to an existing menu rather than a leap into an unsettled category.

As with any regenerative offering, we would encourage you to assess the product documentation and establish your protocols before introducing it.

How EXO|E Fits into a Treatment

EXO|E is applied topically to the skin surface rather than injected. For EXO|E specifically, the product is applied to the skin before any ablative or inflammatory treatment. Within 10 minutes, the active ingredients have penetrated the entire dermal architecture. A topical anaesthetic can then be applied, if required, before the treatment begins. Treatment can then be performed with the product already applied before the inflammatory response begins. The manufacturer’s protocol governs the sequence and should be followed.

This order is worth stating plainly, because protocols differ across products and sources. Some published case work applies exosomes after needling; others use them in combination. For EXO|E, the sequence is to apply first, then needle, and it can also be used before energy-based treatments in line with the manufacturer’s guidance, as it is not broken down by heat.

The Three-Step EXO|E System

EXO|E is a three-step system rather than a single serum. D|TOX is used at home, twice a day for the seven days before treatment, to hydrate and prepare the skin. The EXO|E serum is applied in clinic on the day. RE|PAIR is used at home, twice a day for seven days afterwards, to support the skin while it settles.

In clinic, the order is to apply first, then treat. The full contents of the EXO|E syringe go onto clean skin and are given around ten minutes to absorb. Topical anaesthetic, if you use one, goes on after that. The procedure can then begin. Because EXO|E isn’t degraded by heat, the same sequence works ahead of RF microneedling and fractional laser as it does ahead of conventional needling. The manufacturer’s protocol governs the sequence and should be followed.

A Note on UK Regulation

The regulatory position is the single most important thing to get right, and it turns on the application route and product classification.

Start with the route. The MHRA considers exosomes intended for injection to be medicinal products, and with no exosome injectable holding a UK marketing authorisation, injecting exosomes is not lawful in UK aesthetic practice. Human-derived exosomes are not approved for cosmetic use. This is why the compliant options are topical.

Topical, cosmetic-positioned products are regulated differently, and this is where a common misconception needs clearing up. Cosmetics do not carry a CE or UKCA mark. That marking regime does not apply to cosmetics at all; it covers medical devices, electrical goods, machinery, toys, PPE and similar regulated products. Topical cosmetics are governed instead by the UK Cosmetic Products Regulation, which turns on a different set of obligations:

• A UK-based Responsible Person who holds legal accountability for the product.
• Notification of the product through the Submit Cosmetic Product Notification (SCPN) portal, overseen by the Office for Product Safety and Standards (OPSS).
• A Product Information File that includes a Cosmetic Product Safety Report (CPSR) prepared by a qualified safety assessor.
• Compliant labelling, including the Responsible Person’s details and an ingredient (INCI) list.

Ask your supplier for that documentation.

The cosmetics regulation also expressly excludes anything injected from the definition of a cosmetic, which is a further reason the injectable route sits outside this framework.

Guidance in this area continues to evolve, so this article reflects the position at the time of writing and is not a substitute for regulatory or legal advice. We strongly recommend that every clinic confirms the compliant use of any exosome product for its own setting, checks current MHRA and OPSS guidance, and verifies that its insurance covers the intended use before treating patients. Any suspected adverse reactions should be reported through the MHRA Yellow Card Scheme.

Speak to AMP About EXO|E

If you are considering adding a plant-derived exosome step to your menu, we are happy to talk it through. Arrange a clinical discussion with our team, or explore the full biologics range to see how EXO|E and DE|RIVE fit alongside your existing treatments. Get in touch to start the conversation.

FAQs

What are plant-derived exosomes?

Plant-derived exosomes, or plant-derived extracellular nanoparticles (PDENs), are nanoscale vesicles produced from plant stem cells. They act as biomimetic carriers of skin-compatible factors and are formulated for topical use in aesthetic skincare, most often applied before procedures such as microneedling.

What are the alternatives to plant-derived exosomes?

There are two other sources you will see marketed. Animal-derived exosomes are drawn from animal material such as bovine colostrum, fish or red deer, and are also used topically. Human and stem-cell-derived exosomes come from human biological material and attract much of the research interest, but they are not approved for cosmetic use in the UK. This leaves plant and animal-derived products as the practical topical options.

How do plant-derived and animal-derived exosomes differ?

Both are topical and sit within the UK cosmetics framework, so the difference is one of source and its consequences. Animal-derived material is promoted on its biological proximity to human cells, but carries the sourcing, traceability and patient-sensitivity considerations of any animal ingredient.

Plant-derived material offers a controlled, repeatable starting point and a simpler sourcing profile. The recognised gap for plant material, that no single plant mimics the full human signalling payload, is addressed by formulating with multiple plant extracts rather than one. EXO|E is also a truly topical product and does not need needling into the skin to penetrate the dermal layers. So it goes on before the procedure rather than being needled in afterwards.

Are exosomes legal to use in UK aesthetic clinics?

The position depends on the source and the application route. The MHRA treats injected exosomes as medicinal products, and there is no exosome injectable with a UK marketing authorisation, so injecting exosomes is not lawful in UK aesthetics.

Human-derived exosomes are not approved for cosmetic use. Topical, cosmetic-positioned plant- and animal-derived products are regulated under the UK Cosmetic Products Regulation, but classification depends on the specific product, so clinics should confirm compliant use for their own setting and check current MHRA and OPSS guidance.

How are exosomes applied in treatment?

In UK aesthetic practice, exosome products are applied topically to the skin surface. The sequence depends on the product and the manufacturer’s protocol. EXO|E, for example, is applied to the skin first, before any treatment, and after 10 minutes, the treatment can be performed, or an anaesthetic can be applied (if used) prior to RF microneedling or fractional laser treatment. EXO|E can also be used as a standalone facial treatment without an accompanying device procedure.

The post Plant, Animal and Human Exosomes: What UK Clinics Need to Know appeared first on Aesthetic Medical Partnership.

Their issues do not align neatly with age-segmented categories. A patient in her early fifties may have skin laxity, a softening jawline, loss of tone across the arms and abdomen, and shifting pigmentation, all at once and within a relatively short window.

Treated as separate complaints, the picture becomes a series of disconnected appointments. Treated as what it actually is, a single physiological transition with predictable features, it becomes a clinical pathway.

This is an underserved commercial position. The menopause demographic is sizeable, increasing, and notably loyal once a clinic demonstrates that it understands the underlying physiology rather than selling against the symptoms.

This article presents a four-pillar pathway framework for clinics treating the menopause demographic in 2026, built around devices that can address skin and muscle in the same protocol.

What Happens to Skin During Menopause?

The changes seen in menopausal patients are not simply accelerated chronological ageing. They form a specific physiological cluster driven by declining oestrogen, and understanding that cluster is what separates a targeted pathway from a generic anti-ageing offer.

Collagen and Muscle: The Structural Drop

The foundational work by Brincat and colleagues on post-menopausal skin reported an average decline of around 1 to 2 per cent per year in dermal collagen content.

Running in parallel is a loss of lean muscle mass. Published data described a lean body mass decline of approximately 0.5 per cent per year during the menopausal stage, alongside a 1.7 per cent annual increase in fat mass, with the rate of muscle loss accelerating in the years that follow.

Muscle provides the scaffolding beneath soft tissue, so its atrophy produces a change in contour and support that no skin-surface treatment can fully address.

Barrier, Fat Redistribution and Pigment

Alongside these structural changes, barrier function reduces, leaving skin drier and more reactive; fat redistributes, often centrally; and hormonally influenced pigmentation becomes more prominent. Menopause is a whole-body endocrine transition.

Why Generic Anti-Ageing Protocols Underserve Menopausal Patients

Most clinic menus were built around individual concerns, not a physiological transition. That is where they fall short.

Injectables remain excellent at what they do, but address neither collagen architecture across a region nor underlying muscle tone. Surface radiofrequency improves skin quality and can stimulate dermal collagen, but operates at the level of the skin; it does not reach muscle.

For a patient whose contour change is substantially driven by muscle atrophy, surface RF alone treats one layer of a two-layer problem. Standard body contouring has the inverse limitation, improving fat or muscle parameters while ignoring the skin quality that menopausal patients are often most distressed by.

The menopausal patient lives the physiology daily and can tell when a clinic has or has not understood it.

Menopausal Concern × Modality Matrix

Which Aesthetic Treatments Work Best for Perimenopause? A Four-Pillar Pathway

A pathway matching the physiology needs to address four distinct layers, overlapping in delivery but sequential in logic.

Pillar One: Skin Quality and Barrier

The foundation is barrier function and hydration, both compromised by declining oestrogen. Addressing this first increases the skin’s tolerance of subsequent treatments and gives an early, visible result. Aquafirme XS supports hydration and barrier conditioning as a preparatory and maintenance layer; EXO|E functions as a regenerative topical and post-treatment barrier support, settling the skin after energy-based work.

Pillar Two: Collagen Architecture

This is where the steep post-menopausal collagen decline is directly addressed, and the contrast between dual-action and surface-only RF becomes clinically meaningful. The goal is to address collagen and the muscle layer beneath it as part of one architectural strategy, rather than treating the dermis in isolation and leaving the structural layer for a separate conversation.

Pillar Three: Muscle Tone Restoration

This is the layer most pathways leave out, and the one the physiology makes unavoidable. A pathway that ignores muscle is incomplete by design.

Stim Prime is the natural anchor: its Diatermocontraction technology delivers radiofrequency and electromuscular stimulation in a single combined signal, so collagen stimulation and muscle activation are addressed in the same session. The bQuad facial applicator covers the jawline, neck and décolleté; Thermosculpt and biQuad+ extend the same mechanism across body areas. Jovena FaceStim runs on the same Diatermocontraction technology, so clinics focused solely on facial treatment get the identical collagen-and-muscle mechanism in a single-area platform.

For a demographic whose defining feature is that skin and muscle change simultaneously, a modality that treats them together is a closer match to the underlying biology.

Pillar Four: Body Composition and Contour

The final pillar addresses fat redistribution and loss of contour. Thermosculpt suits the central distribution changes common in this demographic; biQuad+ addresses arms, flanks and other irregular contours.

Because Stim Prime carries both face and body applicators, the body pillar runs on the same platform as the collagen and muscle work.

Why Face and Body Both Matter for This Demographic

Menopausal patients very commonly describe their experience in whole-body terms. A clinic that can only address the face, or only the body, is structurally unable to present a complete answer, no matter how good the individual treatment is. The patient completes the part that the clinic can offer and goes elsewhere for the rest.

Comprehensive pathways retain patients. A device such as Stim Prime, carrying both face and body applicators, lets a single clinic deliver the entire pathway.

For clinics with a more contained need, the sister devices BodyStim and Jovena FaceStim address body and face, respectively, as single-area options. Jovena FaceStim delivers the same Diatermocontraction mechanism as Stim Prime, so the collagen and muscle benefits carry across to the facial-only platform.

Designing the Consultation

Hormonal status should be discussed in the clinical context: whether a patient is perimenopausal or post-menopausal affects the trajectory of her skin and muscle changes and, therefore, the framing of the pathway.

HRT context is relevant at a category level because it provides background for setting expectations; decisions about hormone therapy sit with the patient’s medical practitioner.

A realistic 12-month horizon is usually the right frame, since this is a transition managed over time rather than a single procedure with a fixed endpoint. Where applicable, alignment with the patient’s primary care provider or menopause clinic is good practice.

Photographic standards should be consistent, because a 12-month pathway relies on demonstrating change reliably.

Commercial Considerations

Retention tends to be high because a patient who feels understood does not readily switch. Referral patterns are strong because this demographic talks to peers going through the same transition. Patient lifetime value is correspondingly high.

Course-based pricing models suit the pathway structure: a pathway delivered over 12 months across four pillars lends itself to a course rather than a sequence of one-off transactions, aligning the clinic’s commercial interest with the patient’s clinical result.

The Body Treatment Opportunity sets out the wider revenue case for clinics adding non-invasive body work.

All menopause-related marketing must remain CAP compliant: claims should be substantiated and proportionate, hormone therapy should be discussed only at a category level rather than by naming specific products (as required by CAP rule 12.12), and results claims should reflect what the evidence supports.

Reframing the Pathway

The menopausal patient is not presenting a deficit to be corrected. She is presenting a physiological change with a predictable, well-documented set of features.

The reason generic anti-ageing menus underserve her is not that the individual treatments are poor, but that the menu was never designed around the shift.

A four-pillar approach organises the clinic’s response around the physiology rather than the menu.

Delivered on a face-and-body-capable platform, with Diatermocontraction addressing collagen and muscle in a single signal, it allows a clinic to present one comprehensive plan to a patient who has, until now, mostly been offered fragments.

To walk through how Stim Prime fits into a menopause pathway in your clinic, book a Stim Prime consultation with the AMP clinical team.

Frequently Asked Questions

What happens to skin during menopause?

Declining oestrogen drives a range of changes. Skin collagen decreases substantially in the early post-menopausal years. Lean muscle mass declines at an accelerating rate, barrier function reduces, fat redistributes centrally, and hormonal pigmentation becomes more prominent. It is a distinct multi-system transition, not just older skin.

How does Stim Prime treat menopausal skin and muscle changes?

Stim Prime uses Diatermocontraction, delivering radiofrequency and electromuscular stimulation in a single combined signal. It treats dermal collagen and the underlying muscle in the same session, matching a physiology where skin and muscle change at the same time. Its face and body applicators let one platform deliver the collagen, muscle and contour pillars.

Which aesthetic treatments work best for perimenopause?

A structured four-pillar pathway rather than a single treatment: skin quality and barrier, collagen architecture, muscle tone restoration, and body composition and contour. For a transition defined by simultaneous skin and muscle change, a dual-action RF and EMS approach can match the physiology better than injectables or surface RF alone.

The post The Menopause Patient: Building an Aesthetic Treatment Pathway for Hormonal Skin and Body Change appeared first on Aesthetic Medical Partnership.

Aesthetic clinics are seeing more enquiries from patients who don’t want a full surgical facelift but want more than what injectables alone can provide. And, they’re arriving with a vocabulary that mixes “non-surgical facelift”, “lifting threads” and “endolifting” into one general expectation that something can be done.

Most clinic owners respond by asking which technology is best for facial lifting. That’s the wrong question. The three pathways available aren’t direct competitors. They sit on a scale of invasiveness, downtime, longevity and cost, and the strongest aesthetic clinics tend to offer two of the three, often in combination, with a clear referral relationship for the third.

The question is which pathway is right for your clinic. This article works through that decision: what each pathway actually is, who it’s for, what it asks of your clinic operationally, and how to choose the one that fits the practice you’ve already built.

The Three Pathways at a Glance

Before comparing them, it’s worth understanding what each pathway actually involves, because the language in the market often blurs the differences.

RF Endolifting

Radiofrequency energy is delivered into the subdermal layers via a micro-cannula. It’s minimally invasive, typically performed under local anaesthetic, and depending on the device and protocol, often completed in a single session.

Treatments such as InLift by ThermaDAS sit within this category. Results typically develop over weeks as collagen remodels, with published evidence supporting efficacy in mild to moderate laxity. The treatment targets the jawline, midface and perioral areas, the zones where structural laxity tends to present earliest and where patients are most resistant to surgical intervention.

It’s worth distinguishing RF endolifting from laser endolifting, because the two are often spoken about interchangeably, but the clinical and commercial implications are different. Both use a subdermal micro-cannula delivery method, but the energy source isn’t the same. Laser endolifting (typically a diode fibre, often 1470nm) produces a more aggressive heating profile than the radiofrequency devices.

Laser endolifting carries a higher burn risk because the temperature is harder to control. The laser delivering optical fibre is also fragile, and reports of it snapping when treating a fibrous tissue area (such as when a patient has had HIFU or Sculptra) are common. Consumable costs are also high, and, as such, patient costs tend to be higher.

RF endolifting occupies a different commercial position: more controlled energy delivery, a lower complication profile, and a price point that suits the laxity patient who isn’t ready for the cost or downtime of a more aggressive intervention.

Thread Lifts

Absorbable PDO or PCL threads are inserted under the skin via cannula, providing immediate mechanical lift and longer-term collagen stimulation as the threads dissolve. Thread lifts are minimally invasive, require only local anaesthetic, and the results are visible immediately.

Published multicentre data puts typical longevity at around 6–12 months, depending on thread material, with PDO degrading sooner than PCL. They are best suited to moderate laxity where mechanical repositioning is needed rather than gradual tightening.

Surgical Lifting

This is the traditional facelift, neck lift or mini-lift performed under general or local anaesthetic in a surgical setting. It is the most significant intervention, with the most dramatic and longest-lasting results. It is best suited to substantial laxity beyond what minimally invasive options can address.

Each pathway has a distinct patient profile. The rest of this article is about matching the pathway to the patient and to the clinic.

Patient Suitability

RF endolifting is often suitable for patients aged 35 to 55 with mild to moderate laxity who want subtle but meaningful improvement without downtime. Often, these are patients who have tried injectables and want to address structural laxity that filler alone can’t fix. This may be for a softening jawline, early jowling or perioral laxity in patients who aren’t ready to consider anything more invasive.

Thread lifts often suit patients with moderate laxity, more commonly seen from the early forties onwards. They want an immediate, visible lift and will accept some downtime, along with the small risk of palpability or asymmetry.

They’re useful for patients who need more lift than energy-based devices can deliver but who aren’t candidates for surgery, or simply aren’t interested in it.

Surgical lifting is typically appropriate for patients with significant laxity, often aged 50 and above, where mechanical repositioning of underlying structures is required to achieve the desired result. The patient profile here is substantially different. The conversation is more about anatomical change, not skin quality.

The honest framing: a patient walking through your door asking about “facelift alternatives” could be a candidate for any of the three. The skill is in the consultation, not the device. A clinic that can effectively assess all three categories, even if it only offers one or two in-house, will retain patients and build referral trust in a way that single-pathway clinics rarely manage.

Patient suitability, however, is only half the picture. The other half is whether your clinic can actually deliver the pathway well, and the operational gap between the three is wider than the clinical gap.

What Each Pathway Asks of Your Clinic

The three pathways diverge most sharply in terms of operational and commercial demand, and this is where the realistic options narrow for most practices.

RF Endolifting: Capital Investment, Premium Positioning

A device purchase with a higher per-treatment fee and premium positioning. Practitioner training varies by manufacturer but is typically a short, structured programme for the device itself, though real consultation expertise takes longer.

The pathway needs a single treatment room, no surgical permissions, and consumables are manageable.

Volume is lower than for injectables, but revenue per session is higher, and repeat visits are common. Jawline patients often return for neck or perioral work. It fits neatly into an existing aesthetic clinic without major operational changes. That’s part of why it has gained credibility with medical and dental clinics expanding into aesthetics, and why it suits practices whose brand already relies on technology investment.

Thread Lifts: Lower Capital, Higher Clinical Demand

The spend sits in per-treatment consumables rather than device investment, with a moderate fee often booked in series. Clinically more demanding: requires a medical practitioner trained in injection technique and complication management, comfortable handling bruising, asymmetry and the occasional thread palpability follow-up.

The complication profile is higher than that of energy-based options, with implications for insurance and medical director oversight. Volume potential is higher than for RF endolifting, but the market is more competitive, and consumables erode margin. A strong fit for clinics with high injectable volume already, where the patient base is conditioned to repeat treatment cycles and the practitioner team is comfortable with cannula work.

Surgical Lifting: A Referral Relationship, not an In-Clinic Offering

Theatre, anaesthetist and a full surgical process. Requires a plastic surgeon or facial plastic surgeon, which is why almost no aesthetic clinics offer this in-house. The pathway often reaches the clinic as a referral fee or partnership arrangement, with the highest revenue per patient, but a long sales cycle and low volume.

Useful as a credibility piece and a service to patients who truly need it, but rarely a commercial driver. Clinics that handle this well treat the referral itself as part of their offering rather than a loss of revenue.

Where Stacking Pathways Beats Choosing One

Some of the strongest clinical results come from combining pathways. The most common pairing in aesthetics is RF endolifting with thread lifts, performed either in the same session or in a planned two-stage protocol.

Threads deliver an immediate visible lift through mechanical repositioning of soft tissue. RF endolifting works on a different timeline, gradually tightening the subdermal layer through collagen remodelling over weeks. Used together, the two give the patient a visible result on day one, and they continue to improve as the RF effect develops.

The combination also addresses something neither pathway does well in isolation: threads lift but don’t meaningfully improve skin quality or reinforce the structural scaffold that holds them, and RF tightens but doesn’t reposition tissue that has already descended.

The patients who benefit most have moderate laxity and are in their early forties to early fifties. For them, threads alone would lift but leave skin quality untouched, while RF alone would tighten but do little for visible descent.

It’s also a strong fit for patients whose laxity sits in the grey zone between minimally invasive and surgical candidacy, and for those who want a single considered intervention rather than repeat treatment cycles.

How to Decide What Fits Your Clinic

Three questions are worth answering honestly before committing to a pathway.

What Does Your Existing Patient Base Actually Want?

Pull your last three months of consultation notes and enquiry forms. Count how many patients arrived using thread-related language versus device or “endolift” language. The pathway that matches their existing vocabulary will convert faster than one you have to educate them into, and the data is already in your booking system.

What’s Your Team’s Existing Skill Set?

Be honest about who is going to perform the treatment. If it’s a practitioner who currently spends most of their week on injectables, threads will likely integrate within weeks. If it’s a practitioner already operating energy-based devices, RF endolifting will slot in just as quickly.

Choosing the pathway that demands the steeper learning curve usually means a longer ramp to profitability and a higher rate of treatment-room hesitation in the first six months.

What’s Your Clinic’s Commercial Positioning?

Look at how patients describe your clinic to others. If the recommendation reads as “they have the latest technology”, RF endolifting reinforces that positioning. If it reads as “they’re brilliant with injectables, and you’ll see results immediately”, threads extend it. Choosing the pathway that contradicts your existing brand story is possible but expensive. You’re paying twice: once for the equipment or training, and again to reposition.

Closing

The three pathways aren’t competing technologies. There’s a range of options that can be matched to a patient or combined within a single protocol. The clinics that handle facial lifting best are usually the ones that can honestly assess a patient and recommend the right approach, whether that’s a single pathway, a stacked protocol, or a referral when surgery is the right answer.

If RF endolifting looks like the right fit for your clinic, the natural next step is a closer look at how it sits within the wider skin-tightening category. Our earlier piece, The Clinic Owner’s Guide to Skin Tightening Technology, compares RF, plasma and fractional laser approaches in detail and sets out where InLift ThermaDAS sits within that landscape.

If you’d like to explore how RF endolifting could sit alongside your existing treatment menu, the AMP team can walk you through the clinical and commercial details.

The post RF Endolifting, Thread Lifts or Surgical Lifting: Which Facial Lifting Pathway Fits Your Clinic? appeared first on Aesthetic Medical Partnership.

Many have built successful practices around facial rejuvenation, skin tightening, and injectable treatments, and for good reason. But the market is moving.

Clinics that rely solely on facial treatments are now overlooking one of the most accessible routes to meaningful revenue growth.

A New Category of Patient Demand

Perhaps the most significant driver of body treatment demand in 2025 and 2026 has been the rapid adoption of GLP-1 weight loss medications such as semaglutide and tirzepatide.

According to research published in BMC Medicine, around 1.6 million UK individuals used these medications to support weight loss between early 2024 and early 2025. An additional 3.3 million expressed interest in starting treatment within the next year. The patient pipeline is vast and continues to expand.

Weight Loss Is Only Half the Story

The aesthetic consequences of rapid weight loss are becoming difficult to ignore. A review published in the Journal of Cosmetic Dermatology notes that GLP-1-driven weight loss often results in skin that no longer conforms to the body’s new contours.

These patients look thinner, but they don’t necessarily look toned or feel confident about their shape. This creates a patient who is actively motivated and looking for a non-surgical solution to complete their transformation.

For clinics that can offer targeted body tightening and muscle toning, this is a new demographic walking through the door. The demand isn’t going away.

The Revenue Case for Body Treatments

There is strong commercial logic for adding body treatments to your menu. Body services naturally lend themselves to multiple areas of treatment. A patient who comes in for abdominal toning may also want thigh contouring, glute lifting, or arm tightening. Because of this, body treatments are more easily packaged into treatment courses and have a high average transaction value.

Course-Based Revenue and Operational Efficiency

Body sculpting and toning courses lasting six to eight sessions are common in the category, resulting in predictable, recurring revenue over several weeks. Compared to one-off facial treatments, a body treatment programme often represents a significantly larger per-patient spend. When you factor in the potential for maintenance sessions and cross-referrals into existing facial services, the lifetime value of a body treatment patient can be substantial.

There’s also a practical efficiency benefit. Modern body sculpting platforms like BodyStim are designed to streamline treatment delivery. Built-in pad-placement guidance and real-time thermal sensors enable precise setup and controlled energy delivery, decreasing the complexity of each session.

With dual-subject simultaneous treatment capability, a single device can treat two patients at once, meaning higher revenue per hour from a single piece of equipment compared to procedures that can only serve one patient at a time.

The Timing Advantage

Body treatments in the UK aesthetic market are still in a growth phase. Unlike injectables or skin rejuvenation, where competition is fierce and patient loyalty needs to be earned, body sculpting and toning is a category where many clinics have not yet established a strong position. For facial-focused practices that move now, there is a genuine first-mover advantage in their local market.

Establishing body treatments as part of your clinic’s identity takes time. Patients need to see results from other clients and build confidence in the treatment. Clinics that begin to establish this reputation now will be significantly better positioned when body treatment demand, driven by GLP-1 adoption and broader consumer trends, reaches new heights.

Why Clinics Hesitate When Acquiring New Devices

The most common objection from facial-focused clinics is that body treatments feel like a separate business. The patient demographics seem different, the marketing feels unfamiliar, and the technology requires a new investment. These concerns are understandable, but they are increasingly outdated.

Why the Barriers Are Lower Than You Think

The reality is that most clinics already have the patient base for body treatments. Patients who trust you with their facial aesthetics are ideal candidates for body services. They already have a relationship with your clinic, they are comfortable spending on non-surgical treatments, and many of them are privately wondering whether you offer something for the areas they see in the mirror from the neck down.

Introducing body treatments doesn’t mean building a new audience. It means serving the existing one more completely.

Modern devices fit easily into standard clinic environments and can be operated by existing team members with straightforward onboarding. When acquiring a new device from us, we offer comprehensive training to help you and your team get up to speed as quickly as possible.

While it does require investment, the return timeline for a well-positioned body sculpting device is typically faster than many clinics expect, particularly when treatment courses are sold upfront.

What to Look for in a Body Treatment Platform

Not all body devices are created equal, and clinics entering this space should be discerning about the technology they invest in. The most commercially successful body treatment platforms tend to share a few key characteristics.

Versatility, Efficiency, and Clinical Credibility

A device that only addresses one concern limits your treatment menu and your ability to respond to what patients actually want. The strongest platforms combine muscle stimulation with skin tightening, allowing clinics to address tone, definition, and laxity in a single treatment protocol. This dual action is important for patients losing weight and experiencing muscle loss and skin laxity simultaneously.

Devices that facilitate multi-area or dual-patient treatment allow clinics to maximise throughput without sacrificing results. The ability to treat several body zones in a single session has a direct impact on revenue per hour.

Third is clinical credibility. In an increasingly educated market, patients are doing their research before they book. A body treatment device backed by visible clinical results and a clear mechanism of action provides both the clinic and the patient confidence in the investment.

Where BodyStim Fits

For clinics evaluating their options, BodyStim by Imperium is worth a close look. It combines RF diatermocontraction (a controlled radiofrequency signal that triggers both deep heating and muscle contraction) with neuromuscular stimulation, delivering both skin tightening and muscle toning through a single platform.

Three treatment modes (Thermosculpt™, biQuad+™, and Hybrid) allow practitioners to customise protocols to meet particular patient goals, including deep muscle activation, targeted contour refinement, or a combination of both.

Built for Clinic Profitability

BodyStim supports dual-patient treatment, meaning two people can be treated simultaneously. For busy clinics looking to maximise the commercial return on a single device, this is a significant operational advantage.

Importantly, BodyStim aligns with the specific clinical needs of patients who have recently lost significant weight. Its combination of muscle toning and skin tightening makes it well-suited to the growing number of post-weight-loss patients now seeking non-invasive body treatments.

Take the Next Step

If you’re thinking about whether body treatments are a good fit for your clinic, we’d love to talk.

We work with clinics across the UK to identify the right technology for their goals and growth stage. Whether you’re starting from scratch with body services or looking to upgrade from a basic platform, our team can help you model the revenue potential and find the right fit.

Get in touch with our team to book a BodyStim demonstration or discuss how body treatments could fit into your clinic’s growth strategy.

The post The Body Treatment Opportunity: Why Facial-Only Clinics Are Leaving Revenue on the Table appeared first on Aesthetic Medical Partnership.

Led by Dr Sary Kadar, Medical Director of Estar Medical and a recognised expert in autologous regenerative therapies, this webinar combines clinical insight with hands-on experience. With a strong focus on PRP applications across dermatology, skin rejuvenation and hair restoration, it offers valuable guidance for practitioners looking to deliver more predictable, natural-looking results.

The post Cellenis PRP for Hair Restoration Webinar | Dr Sary Kadar appeared first on Aesthetic Medical Partnership.